Cambridge Investment Research Advisors, Inc. Bridge Bio Pharma, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 23,805 shares of BBIO stock, worth $844,839. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,805
Previous 15,263
55.97%
Holding current value
$844,839
Previous $389,000
67.87%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding BBIO
# of Institutions
320Shares Held
176MCall Options Held
13MPut Options Held
2.48M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY25.3MShares$897 Million44.98% of portfolio
-
Viking Global Investors LP25.1MShares$892 Million2.33% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.1MShares$535 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$442 Million0.01% of portfolio
-
State Street Corp Boston, MA6.18MShares$219 Million0.01% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $5.26B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...